1. Home
  2. BAH vs KRYS Comparison

BAH vs KRYS Comparison

Compare BAH & KRYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Booz Allen Hamilton Holding Corporation

BAH

Booz Allen Hamilton Holding Corporation

HOLD

Current Price

$60.78

Market Cap

9.6B

ML Signal

HOLD

KRYS

Krystal Biotech Inc.

HOLD

Current Price

$364.47

Market Cap

10.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BAH
KRYS
Founded
1914
2015
Country
United States
United States
Employees
31500
N/A
Industry
Professional Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.6B
10.3B
IPO Year
2010
2017

Fundamental Metrics

Financial Performance
Metric
BAH
KRYS
Price
$60.78
$364.47
Analyst Decision
Hold
Strong Buy
Analyst Count
11
11
Target Price
$97.00
$297.60
AVG Volume (30 Days)
2.1M
310.2K
Earning Date
05-22-2026
05-04-2026
Dividend Yield
3.09%
N/A
EPS Growth
N/A
128.00
EPS
6.90
1.83
Revenue
$11,217,000,000.00
$389,130,000.00
Revenue This Year
N/A
$38.74
Revenue Next Year
$2.14
$32.53
P/E Ratio
$8.66
$196.81
Revenue Growth
N/A
33.94
52 Week Low
$59.63
$130.50
52 Week High
$120.05
$362.40

Technical Indicators

Market Signals
Indicator
BAH
KRYS
Relative Strength Index (RSI) 24.54 75.20
Support Level N/A $253.89
Resistance Level $82.42 N/A
Average True Range (ATR) 2.73 12.58
MACD -1.77 3.65
Stochastic Oscillator 6.62 89.65

Price Performance

Historical Comparison
BAH
KRYS

About BAH Booz Allen Hamilton Holding Corporation

Booz Allen Hamilton Holding Corp provides technology solutions in areas such as artificial intelligence, cybersecurity, and related fields. The company serves U.S. federal government agencies, commercial clients, and select international customers. It also provides technologies to evolve defense missions and delivers solutions to warfighters in the digital battlespace.

About KRYS Krystal Biotech Inc.

Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.

Share on Social Networks: